Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cusatuzumab plus azacitidine in newly diagnosed AML not eligible for intensive chemotherapy
2019-000473-23Phase 2Active
- Sponsor
- OncoVerity
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cusatuzumab in acute myeloid leukemia (AML), sponsored by OncoVerity. Primary endpoint: Complete response (CR) rate per ELN 2017. Started Jul 2019; status: active.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-000473-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000473-23.